Physician profile
Manuel E Gordillo
NPI 1346347887
$3,352.77
in general payments reported to CMS, 2019-2025
12 companies · $46.22 in 2025
The $46.22 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $99.00 · 2022: $150 · 2023: $2,336 · 2024: $552 · 2025: $46.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,173 · Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,173.00 |
| Food and Beverage | $761.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cashflow Solutions, LLC | $2,173.00 | 2023 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
| Astellas Pharma US INC | $347.98 | 2019-2022 | |
| Organogenesis INC. | $161.60 | 2019-2024 | Apligraf |
| Teva Pharmaceuticals USA, INC. | $125.01 | 2024 | Austedo Xr |
| Mimedx Group, INC. | $125.00 | 2024 | |
| Viiv Healthcare Company | $125.00 | 2024 | Dovato |
| Gilead Sciences, INC. | $118.59 | 2023 | Epclusa |
| Smith+Nephew, INC. | $86.27 | 2019-2024 | Grafix Pl |
| Insmed, INC. | $56.56 | 2023-2025 | Arikayce |
| Abbvie INC. | $17.69 | 2023 | |
| Biomerieux INC | $16.07 | 2025 | Filmarray Bcid Panel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Gordillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.